Plain-English translation of NCT05694858 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new way to numb your skin before a blood draw. Researchers are comparing a microneedle patch loaded with lignocaine—a numbing medication—against a standard numbing cream patch (EMLA) to see which one reduces pain better. Both contain the same amount of numbing medication and are applied to your hand for 30 minutes before the blood draw.
Blood draws can be uncomfortable, especially for people who are anxious about needles. This trial aims to find out whether the new microneedle delivery method might work faster or more effectively than the standard cream patch, potentially making the experience less painful for patients.
You likely qualify if…
You likely don't qualify if…
On the day of your visit, you'll have your vital signs checked and answer questions about your health. Then one of two numbing patches will be applied to the back of your hand—either the new microneedle patch or the standard cream patch. After 30 minutes, the patch will be removed and a nurse will draw blood. The study team will monitor you to ensure the patch is safe and check how well it worked at reducing pain during the blood draw.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Malaysia